Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.57 |
| ▸ | BLM | P54132 | 1/20 | 0.55 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.52 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.52 |
| ▸ | FAAH | O00519 | 1/20 | 0.49 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12092729 | 0.94 | ACE2 (0.66) | ACE2BLMFFAR1FFAR4FAAH | |
| SCHEMBL1516556 | 0.91 | — | — | |
| SCHEMBL22555 | 0.91 | — | — | |
| SCHEMBL1532456 | 0.91 | — | — | |
| SCHEMBL293989 | 0.89 | ACE2 (0.71) | ACE2FFAR1FFAR4FAAHGPR84 | |
| SCHEMBL13730236 | 0.89 | ACE2 (0.71) | ACE2FFAR1FFAR4FAAHGPR84 | |
| SCHEMBL8586725 | 0.89 | ACE2 (0.71) | ACE2FFAR1FFAR4FAAHGPR84 | |
| SCHEMBL2732619 | 0.89 | ACE2 (0.63) | ACE2BLMFFAR1GPR84CA2 | |
| SCHEMBL8031688 | 0.89 | ACE2 (0.63) | ACE2BLMFFAR1GPR84CA2 | |
| SCHEMBL2732633 | 0.89 | ACE2 (0.63) | ACE2BLMFFAR1GPR84CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111448204-B | Vaccine against klebsiella pneumoniae | 爱杜西亚药品有限公司 | 2024-05-14 | — | — | CN | disclosed |
| US-11891413-B2 | Vaccine against Klebsiella pneumoniae | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-02-06 | — | — | US | disclosed |
| US-20210386845-A1 | VACCINE AGAINST KLEBSIELLA PNEUMONIAE | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-12-16 | — | — | US | disclosed |
| EP-3717498-A1 | VACCINE AGAINSTKLEBSIELLA PNEUMONIAE | Vaxxilon AG (CH) | 2020-10-07 | — | — | EP | disclosed |
| CN-111448204-A | Vaccine against klebsiella pneumoniae | 瓦希隆股份公司 | 2020-07-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11891413-B2 | Vaccine against Klebsiella pneumoniae | UBXN1, MLX, UBXN4 | ACE2 2576/4885BLM 3393/4885FFAR1 2142/4885 |
| US-20210386845-A1 | VACCINE AGAINST KLEBSIELLA PNEUMONIAE | UBXN1, MLX, UBXN4 | ACE2 2576/4885BLM 3393/4885FFAR1 2142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.